Sage — The Metabolic Hypothesis of Arterial and Venous Occlusions

← Sage — Ophthalmology · Sage — Eye · Sage hub

Sage — The Metabolic Hypothesis of Arterial and Venous Occlusions

Occlusion as Catastrophic Mismatch: When the Flux Manager Fails the Conduit

Disclaimer · This essay presents a metabolic and evolutionary hypothesis developed through first-principles reasoning, integration of mechanistic biology, clinical patterns (particularly from ophthalmology), and the unifying EnSurf metabolic framework. It is offered for educational and philosophical purposes only. It is not medical advice, diagnosis, or treatment. Statins, GLP-1 receptor agonists, antiplatelet agents, anticoagulants, and other pharmacologic tools have robust evidence for specific indications in appropriately selected patients; they are not dismissed. Individual responses vary widely. Decisions about starting, continuing, or stopping any prescription medicine, or about significant changes to diet, lifestyle, or supplements, belong solely to a patient and a qualified clinician who know the full clinical context. Readers with existing vascular disease, crowded optic discs, or who take nitrates or other vasoactive drugs should consult their physician before making changes.

The eye is a high-resolution prototype of vascular failure. Its arteries and veins are small, share adventitial sheaths where they cross and inside the optic nerve, and serve tissue that reports injury within minutes as lost vision. Central and branch retinal artery occlusions, and central and branch retinal vein occlusions, therefore function as clinical microscopes. They make visible, at the scale of a single vascular bed, the same upstream processes that later declare themselves as coronary occlusion, cerebral infarction, deep-vein thrombosis, or pulmonary embolism. The traditional separation of “arterial” and “venous” disease is clinically useful and mechanistically incomplete. This hypothesis proposes that both may share a metabolic contribution: progressive loss of coupled endothelial nitric oxide and mitochondrial competence in the vessel wall. In this model, the catastrophic events—embolus, in-situ thrombosis, compressive venous stasis, hemorrhage, infarction—may be downstream expressions of that root rather than necessarily independent diseases.

This essay places arterial and venous occlusion inside the mitochondrial-metabolic hypotheses of atherosclerosis and of nitric oxide. This essay treats the retina as the proving ground, then scales the same logic to the organism. It also examines how dashboard interventions (statins, GLP-1 receptor agonists) can modulate downstream cascades while leaving the engine unrepaired, and how ferritin metabolism—iron sequestration as a sentinel of redox and bioenergetic coherence—may contribute to the prothrombotic milieu of venous occlusion.

Where Separate Disease Models Fall Short

Standard teaching distinguishes arterial from venous occlusion by hemodynamics and thrombus composition. Arterial events occur under high shear. They are driven by atherosclerotic plaque rupture or embolism and produce platelet-rich (“white”) thrombi that starve downstream tissue of oxygen. Venous events occur under low shear. They follow Virchow’s triad—stasis, endothelial injury or activation, and hypercoagulability—and produce fibrin- and erythrocyte-rich (“red”) thrombi that raise hydrostatic pressure, leak, and secondarily ischemia. In the eye the distinction is sharp: retinal artery occlusion behaves as an ocular stroke with high subsequent systemic vascular risk; retinal vein occlusion is more often managed as a local congestive and edematous problem, though it too tracks cardiovascular risk factors [1, 2, 3].

These descriptions are accurate as far as they go. They do not explain why the same middle-aged patient develops both, why endothelial dysfunction appears years before either event, why lean individuals with efficient mitochondria can carry high apoB without plaque while insulin-resistant individuals progress at modest particle numbers, or why interventions that restore laminar shear and mitochondrial oxidative capacity reduce risk of both arterial and venous events more reliably than interventions aimed only at the final thrombus. Treating the two as separate disease families requires multiple independent inputs (lipids, hypertension, hypercoagulability, local anatomy) converging by coincidence. A single upstream failure of energy-flux management is proposed here as a unifying hypothesis, not an established explanation [4].

The Metabolic Hypothesis

In this hypothesis, arterial and venous occlusions are interpreted as catastrophic mismatches between mitochondrial demand and the ability of the conduit to deliver oxygen and substrate while remaining patent. The proposed primary defect is the progressive uncoupling of endothelial nitric oxide synthase and the mitochondrial inefficiency that both produces and is worsened by that uncoupling. Atherosclerosis is the arterial expression of conduit failure. Venous occlusion is proposed to be a low-shear expression of related endothelial and rheologic vulnerability, amplified by local anatomy and stasis.

Nitric oxide remains the short-range flux manager. It opens feed arteries in response to shear, modestly rations oxygen consumption at cytochrome c oxidase so proximal mitochondria do not monopolize the terminal acceptor, and restrains leukocyte adhesion, platelet activation, and smooth-muscle proliferation so the lumen stays competent. When eNOS is coupled and mitochondria oxidize cleanly, high energy flux is possible without proportional damage. When oxidative stress uncouples eNOS, the enzyme produces superoxide, which can react with nitric oxide to form peroxynitrite [5, 6]. Delivery fails, matching fails, and the wall begins the program that ends in plaque or in a vein that can no longer tolerate ordinary compression and stasis.

In arterial territories the failure is expressed as atherogenesis. Endothelial permeability rises, apoB particles are retained, oxidized, and taken up by macrophages whose own mitochondria are impaired. Foam cells, fibrous caps, and necrotic cores follow. The final occlusion may be plaque rupture with superimposed thrombosis or embolism from a distant unstable site; this model places loss of tonic NO and mitochondrial distress upstream of retention and inflammation [4, 5]. The retina simply makes the endpoint dramatic: an embolus or local thrombus in the central retinal artery takes vision within seconds, and the retina turns pale with a cherry-red spot over the following hours, because the inner retina has almost no collateral reserve. Early on, the fundus can still look almost normal.

In venous territories the same endothelial impairment meets different local physics. At arteriovenous crossings the artery and vein share an adventitial sheath. Arteriosclerotic stiffening of the artery narrows the vein, produces turbulent flow, and injures endothelium. In the lamina cribrosa the central retinal artery and vein are likewise enclosed together. Elevated intraocular pressure further impedes venous outflow. When the endothelium is already adhesive and prothrombotic from NO loss, ordinary compression and modest hyperviscosity are sufficient to initiate thrombus. The resulting congestion raises hydrostatic pressure, breaks the blood-retinal barrier, and produces the hemorrhages, edema, and secondary ischemia of retinal vein occlusion [3]. Systemically the same logic operates in valve pockets of the deep veins: hypoxia of the avascular cusp endothelium, leukocyte recruitment, and local tissue-factor expression on a background of systemic hypercoagulability that itself tracks insulin resistance and mitochondrial dysfunction.

The hypothesis proposes that the two pathways may share an upstream metabolic contribution, with geometry and shear influencing how vulnerability becomes occlusion. Atherosclerosis is not required for every venous event, yet the endothelial vulnerability that permits venous thrombosis is the same vulnerability that permits arterial plaque. Hypercoagulable states, dehydration, and hormonal modulation of clotting factors act as precipitants on a prepared surface; they are not the root.

Ferritin, Iron Handling, and the Prothrombotic Milieu

Ferritin is conventionally read as a storage ledger of iron atoms. A metabolic reading treats it as an active sentinel of bioenergetic integrity and redox coherence. Iron is indispensable for iron-sulfur clusters and heme in the electron-transport chain and dangerous as a Fenton catalyst. When the cell registers rising reactive oxygen species (via Nrf2) or inflammatory cytokines (via STAT3, NF-κB, and hepcidin), it upregulates ferritin to sequester ferrous iron as ferric iron inside the protein cage. The result is protective containment. In chronic low-grade redox and inflammatory states—the same states that uncouple eNOS and impair mitochondrial quality control—this sequestration becomes persistent. Transferrin saturation may fall while ferritin rises. Functional iron availability for erythropoiesis and for mitochondrial biogenesis is restricted even as stored iron is adequate or elevated. Labile iron that escapes containment continues to generate localized oxidative damage [7, 8].

This pattern is relevant to venous hypercoagulability. Endothelial cells under chronic redox pressure express more adhesion molecules and tissue factor. Macrophages sequestering iron release mtDAMPs and cytokines that further activate coagulation. Iron deficiency itself (or functional iron deficiency) is associated with reactive thrombocytosis and endothelial dysfunction that favor thrombosis [9]. Metabolic hyperferritinemia, common in insulin resistance and fatty liver, tracks the same bioenergetic milieu that elevates apoB and impairs NO bioavailability. In the eye, where shared sheaths already concentrate mechanical stress onto the venous wall, this hypothesis holds that an endothelium whose iron handling is shifted toward containment rather than clean utilization may be more readily driven across the threshold into thrombus by ordinary compression or modest stasis. That chain has been shown in iron-deficient rats and in general iron biology, not yet as a proven human retinal pathway [7–9]. Ferritin is not the cause of occlusion. In this interpretation, it may signal prioritization of iron containment during redox stress rather than free iron distribution in service of oxidative phosphorylation. The hypothesis predicts that resolving the threat—by restoring fuel quality, shear, and circadian amplitude—might lower the drive to sequester and improve the functional iron available for mitochondrial and endothelial repair.

The Eye as Prototype and as Canary

Retinal vessels are an experimental system that evolution and clinical medicine have already built. They are optically accessible, small enough that single emboli or focal thrombi produce measurable field defects, and anatomically arranged so that arterial disease directly injures the companion vein. Branch retinal vein occlusion almost always occurs at an arteriovenous crossing, usually where the artery lies over the vein [3]. Central retinal vein occlusion occurs where the vessels share the fibrous envelope of the lamina cribrosa. These sites concentrate the mechanical consequence of arterial stiffening onto the venous wall. The eye is proposed here to display, in one vascular bed, the following sequence: mitochondrial and NO failure in the arterial wall → arteriosclerosis and endothelial dysfunction → local venous compression and endothelial injury → thrombosis → congestion, hemorrhage, macular edema, and ischemia.

The clinical epidemiology follows. Both retinal artery and vein occlusions rise with age and with the classic metabolic risk factors [2, 3, 10]. Arterial occlusions carry a clearer short-term stroke and cardiac risk because they more often represent embolization from unstable extracranial or cardiac sources—the same sources that threaten the brain. Venous occlusions track hypertension, glaucoma, and the metabolic syndrome more tightly and carry a lower but still elevated systemic risk. In younger patients without conventional risk factors, thrombophilia (antiphospholipid antibodies, factor V Leiden, hyperhomocysteinemia) becomes visible precisely because the background endothelial resilience is higher; the precipitant must be stronger. The prototype predicts that interventions restoring laminar shear, coupled eNOS, and mitochondrial oxidative capacity will reduce both events, while interventions aimed only at the final clot will treat the catastrophe after the conduit has already failed.

The optic nerve head adds a further watershed. Non-arteritic anterior ischemic optic neuropathy is an ischemic injury of the front of the optic nerve that usually occurs in a crowded disc (a small disc with little or no cup) [11]. How it starts is still not fully known. Crowded anatomy and poor perfusion reserve are the best-supported associations; nocturnal blood-pressure dips have been proposed as a final insult in some people. On this hypothesis, a bioenergetic shortfall in high-demand axons may also play a part. Axonal transport fails, the disc swells in a tight scleral canal, and vision is often permanently cut. This anatomy is thought to be especially sensitive to sudden changes in perfusion pressure, nocturnal blood pressure, viscosity, and nutrient delivery [11]. It is also a tissue whose axons are lifelong and cannot be freely recycled from stem-cell pools. The untested hypothesis is that, when interventions change load and substrate availability faster than mitochondrial capacity can adapt, the optic nerve could be a site of injury.

Dashboard Interventions and the Optic Nerve

Statins inhibit HMG-CoA reductase at the mouth of the mevalonate pathway. Cholesterol is one product; ubiquinone (CoQ10), dolichols, and isoprenoids required for protein prenylation are others. CoQ10 is the mobile electron carrier between complexes I/II and III. Experimental systems show statin effects on membrane potential, respiratory complexes, and mitochondrial ROS [12]. In secondary prevention they reduce plaque events, and some observational studies associate their use with lower rates of retinal vascular occlusion and with reduced subsequent cardiovascular events after either arterial or venous occlusion. These benefits are real and operate largely by lowering circulating apoB substrate, stabilizing plaque, and modulating inflammatory cascades [13, 14, 15, 16]. They do not restore oxidative phosphorylation capacity in the vascular wall or in high-demand axons. They are sophisticated dashboard work. Over-emphasizing them as engine repair confuses a lower particle number and quieter intima with rebuilt mitochondrial reserve.

GLP-1 receptor agonists override appetite circuits, gastric emptying, and glucose-dependent insulin secretion. Weight, glucose, and often MACE improve [17]. They do not repair electron-transport function [18]. In some trials a large share of weight lost is lean mass, though the share varies widely and lean mass is not the same as muscle. Rapid glycemic change can alter microvascular flow and nutrient delivery. In the combination—statin taxing mevalonate products while GLP-1 rewrites phenotype and often spends lean mass—the dashboard turns greener while the gap between ATP supply and demand may widen in watershed tissues. Observational signals of roughly two-fold increased NAION risk with semaglutide are compatible with a low-absolute-incidence tail-risk energy-failure lesion inside a beneficial average MACE curve. Absolute excess is small (on the order of one extra case per ten thousand person-years in some estimates) [19, 20]. On this hypothesis, the mechanism is not “two toxins” but reduced ETC reserve plus forced phenotype change plus a green dashboard that hides the gap, concentrated where crowded discs, sleep apnea, and nocturnal hypotension (reported NAION risk factors) coincide with rapid early weight and A1c decline, high-intensity statin, and low baseline muscle.

Neither drug is dismissed. Both can buy time by unloading the vessel wall and lowering inflammatory drive. The incomplete act is to stop there and call the patches health. The complete act is to use the time for fuel that mitochondria oxidize cleanly, circadian amplitude that times biogenesis and redox rhythms, and strength that writes shear and raises apoptosis thresholds in lifelong cells. Sudden monocular vision loss on the combination is an energy emergency, not a curiosity.

Sudden loss of vision in one eye, even if it clears, is an emergency: go to an emergency department right away, because a blocked eye artery is treated like a stroke. In anyone over 50, new headache, jaw pain when chewing, or scalp tenderness with vision loss can mean giant cell arteritis, which needs treatment the same day to protect the other eye. Anyone on semaglutide or a similar drug who has sudden vision loss should also tell the prescribing physician without delay.

Scaling to the Organism

The same architecture operates at larger scale. Coronary occlusion is the cardiac expression of the arterial pathway: plaque rupture or erosion on a background of endothelial NO loss and macrophage mitochondrial distress. In this model, cerebral arterial infarction may involve overlapping processes in the carotid or intracranial tree. Peripheral arterial occlusion is the same process in larger conduits that serve skeletal muscle. In each case the final thrombus is the event that brings the patient to attention; the decades-long preparation of the wall is the disease.

Venous thromboembolism follows the low-shear pathway. Prolonged immobility, surgery, or pregnancy supplies stasis. Cancer, inflammation, or hormonal states supply hypercoagulability. The prepared endothelium—already expressing adhesion molecules and tissue factor because of chronic NO loss and mitochondrial impairment—supplies the third element of Virchow’s triad. Obesity and insulin resistance appear in both arterial and venous risk tables because they are systemic expressions of the same cellular energy failure: impaired oxidative phosphorylation, compensatory hyperinsulinemia, hepatic over-secretion of apoB particles, and a redox environment that uncouples eNOS. Ferritin elevation in this setting is often the sentinel reporting that iron is being held because the system perceives ongoing redox threat.

Discordant phenotypes are explained rather than treated as exceptions. Lean individuals with high energy flux, intact glycocalyx, and coupled eNOS can tolerate elevated apoB particle numbers with little plaque because the wall remains competent to handle the particles it encounters. Individuals with mitochondrial inefficiency develop endothelial dysfunction, retention, and inflammation at lower particle numbers. The dashboard (apoB, blood pressure, glucose, ferritin) moves because the engine has already failed. Occlusion, arterial or venous, is the point at which the failed engine can no longer keep the conduit patent under ordinary load.

Therapeutic Implications Inside EnSurf

If both arterial and venous occlusions are downstream of mitochondrial and nitric-oxide failure, prevention and treatment begin with restoration of the flux manager and the engine it serves.

Fuel that mitochondria oxidize cleanly reduces electron leak and the superoxide that uncouples eNOS. Animal proteins and fats, metabolizable carbohydrates in physiologic amounts, and strategic fasting lower the ambient oxidative load. Fasting is not safe for everyone. People taking insulin or other blood-sugar-lowering drugs, people with a primary mitochondrial disease or a heart-rhythm problem, and anyone pregnant should fast only under their physician's care, and fasting should never mean going short on fluids, since dehydration thickens the blood. Circadian alignment—morning light, consistent sleep, dim evenings—supports the daily transcription of eNOS, tetrahydrobiopterin synthesis, and mitochondrial quality control. Strength and conditioning supply the repeated laminar shear that phosphorylates eNOS acutely and writes more of the enzyme over time, while raising tissue mitochondrial volume. Grip strength and functional capacity are proposed as practical, nonspecific surrogates of the whole stack. Where iron handling is shifted toward sequestration, these inputs can reduce the chronic redox and inflammatory signals that drive excessive containment, improving functional iron availability without reflexive supplementation or chelation.

Pharmacologic amplifiers have defined places as bridges, not substitutes. Statins lower apoB and modulate inflammatory cascades; they retain a role in secondary prevention and advanced disease. Antiplatelet agents address the high-shear, platelet-rich phase of arterial thrombosis. Anticoagulation has a place when a physician finds atrial fibrillation or a clinically significant clotting disorder that calls for it; it is not a routine treatment for retinal vein occlusion itself. PDE5 inhibitors amplify residual NO–cGMP signaling and may improve endothelial function in men who already have impairment; they do not restore a pulse that is absent, and they carry a rare reported association with NAION [21], most often discussed for eyes that already have a crowded optic disc. A pooled look at the studies did not find a clear overall rise in risk, though some drug-specific analyses did; causation is not settled. GLP-1 agonists can reduce load and inflammatory drive in selected patients. None of these agents replace the shear, fuel, and circadian conditions that keep eNOS coupled and mitochondria competent.

The ordering remains engine first. The hypothesis predicts that, when mitochondrial oxidative capacity and laminar shear are restored, endothelial NO bioavailability may rise, adhesion and permeability fall, and both the arterial wall and the venous endothelium become more tolerant of ordinary mechanical and rheologic stress. ApoB, blood pressure, glucose, and ferritin often improve as dashboard readings of that restoration. In advanced or genetically driven disease the dashboard may still require direct pharmacologic attention; the hypothesis predicts that such attention will be more effective, and residual risk lower, when the engine is no longer the constraint.

Conclusion

Arterial and venous occlusions are not two diseases that happen to share risk factors. This hypothesis interprets them as potentially different geometric expressions of a shared metabolic contribution: the progressive inability of the vascular wall to maintain coupled nitric oxide and competent mitochondria under the loads of ordinary life. Atherosclerosis is the high-shear scar. Venous thrombosis is the low-shear scar. Ferritin elevation is often the sentinel reporting that iron is being contained because redox and inflammatory threat has been registered. The eye, with its shared sheaths, optical accessibility, and immediate functional readout, is the prototype that makes the sequence visible before it declares itself in the heart, brain, or leg. The optic nerve head is the canary that can declare when dashboard rewrites of load and substrate outrun unrepaired reserve.

The remainder of the EnSurf framework is unchanged. Fuel, circadian coherence, and work that writes shear and mitochondrial volume remain the primary interventions. Amplifiers of cGMP, reducers of apoB, and inhibitors of platelet or coagulation pathways are tools for moments when the pulse is weak or the conduit is already compromised. They are not substitutes for restoring the manager that stands between blood and mitochondrion. When that manager is coupled and the toll-keeper is supplied, high energy flux remains possible without the conduit becoming the disease. When the manager fails, delivery fails, matching fails, and occlusion—arterial or venous—is the catastrophe the organism eventually reports.

This essay synthesizes published mechanisms in nitric oxide biology, vascular physiology, mitochondrial respiration, atherosclerosis, iron handling, and the pharmacology of statins and GLP-1 receptor agonists as of 2026. It is a hypothesis, not medical advice. Individual evaluation by a qualified physician remains essential.

Statins, GLP-1 receptor agonists, antiplatelet agents, anticoagulants, PDE5 inhibitors, and nitrates are prescription medicines used only under a physician’s guidance; nothing on this page is a regimen. PDE5 inhibitors must never be combined with nitrates. Talk with your own physician before changing anything.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised November 6, 2026.

References

Mackman N Triggers, targets and treatments for thrombosis. Nature 2008. doi:10.1038/nature06797. PMID 18288180. Review supports the distinct hemodynamic and thrombotic pathways and Virchow factors, not a single obligatory mitochondrial root.
Mac Grory B, Schrag M, Biousse V, et al. Management of Central Retinal Artery Occlusion: A Scientific Statement From the American Heart Association. Stroke 2021. doi:10.1161/STR.0000000000000366. PMID 33677974. AHA scientific statement: CRAO is acute ischemic stroke and an emergency with further systemic vascular risk. Does not establish the proposed mitochondrial-first cause or exact retinal-sign timing.
Nicholson L, Talks SJ, Amoaku W, et al. Retinal vein occlusion (RVO) guideline: executive summary. Eye (London, England) 2022. doi:10.1038/s41433-022-02007-4. PMID 35301458. RVO guideline supports crossing/lamina thrombus anatomy and edema/ischemia. Explicitly distinguishes RVO associations from systemic venous occlusions; routine thrombophilia testing and anticoagulation are not supported for isolated RVO. Does not support universal NO/mitochondrial causation.
Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European heart journal 2017. doi:10.1093/eurheartj/ehx144. PMID 28444290. Convergent genetic, epidemiological and intervention evidence establishes LDL causality. A metabolic phenotype has not been shown to erase particle-exposure risk.
Förstermann U, Sessa WC Nitric oxide synthases: regulation and function. European heart journal 2012. doi:10.1093/eurheartj/ehr304. PMID 21890489. Mechanistic review supports eNOS biology, uncoupling and vasoprotection; pharmacologic restoration of eNOS function, including statins, also described. Does not establish that all arterial/venous events have one mitochondrial root.
Brown GC, Cooper CE Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. FEBS letters 1994. doi:10.1016/0014-5793(94)01290-3. PMID 7805858. Brain synaptosomes and isolated cytochrome oxidase demonstrate reversible NO/oxygen competition; redistribution of oxygen across whole human vascular beds is an extrapolation.
Ganz T, Nemeth E Iron homeostasis in host defence and inflammation. Nature reviews. Immunology 2015. doi:10.1038/nri3863. PMID 26160612. Review supports inflammation-related iron sequestration and iron regulation; not proof of the proposed ferritin-to-retinal-thrombosis or lifestyle-reversal chain.
Valenti L, Corradini E, Adams LA, et al. Consensus Statement on the definition and classification of metabolic hyperferritinaemia. Nature reviews. Endocrinology 2023. doi:10.1038/s41574-023-00807-6. PMID 36805052. Consensus supports association of metabolic hyperferritinemia with metabolic/liver disease, not serum ferritin as a specific mitochondrial readout or proven thrombosis treatment target.
Jimenez K, Leitner F, Leitner A, et al. Iron deficiency-induced thrombocytosis increases thrombotic tendency in rats. Haematologica 2021. doi:10.3324/haematol.2019.245092. PMID 32079699. Iron-deficient rats developed thrombocytosis and larger thrombi. Not direct proof of functional iron deficiency causing human RVO or benefit of the proposed lifestyle approach.
Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010. doi:10.1016/j.ophtha.2009.07.017. PMID 20022117. Population-based pooled analysis supports rising RVO prevalence with age; not a common mitochondrial cause or a direct RVO-versus-RAO systemic-risk ranking.
Miller NR, Arnold AC Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy. Eye (London, England) 2015. doi:10.1038/eye.2014.144. PMID 24993324. Review supports typical small/crowded discs and ischemic optic neuropathy; pathogenesis incompletely understood. Does not establish drug-combination ETC failure or every proposed perfusion factor.
Broniarek I, Dominiak K, Galganski L, et al. The Influence of Statins on the Aerobic Metabolism of Endothelial Cells. International journal of molecular sciences 2020. doi:10.3390/ijms21041485. PMID 32098258. Endothelial-cell experiment: atorvastatin altered respiration and CoQ10; ATP levels and viability were unchanged. Does not establish optic-nerve injury in treated patients or a statin/GLP-1 interaction.
Chien CC, Chen PH, Chung CH, et al. Association between Statins and Retinal Vascular Occlusion: A Population-Based Cohort Study. International journal of environmental research and public health 2021. doi:10.3390/ijerph18189864. PMID 34574786. Observational Taiwan cohort associates statin use with fewer retinal vascular occlusions; nonrandomized association, not a causal treatment result.
Yoo J, Shin JY, Jeon J, et al. Impact of statin treatment on cardiovascular events in patients with retinal vein occlusion: a nested case-control study in Korea. Epidemiology and health 2023. doi:10.4178/epih.e2023035. PMID 36996869. Korean nested case-control study associates statins with lower subsequent cardiovascular events after RVO; not randomized efficacy for the ocular occlusion.
Yoo J, Jeon J, Shin JY, et al. Statin Treatment on Cardiovascular Risk After Retinal Artery Occlusion: A Historical Cohort Study. Journal of epidemiology and global health 2023. doi:10.1007/s44197-023-00143-y. PMID 37572209. Historical Korean RAO cohort associates statins with lower subsequent cardiovascular events; not randomized prevention of recurrent retinal occlusion.
Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (London, England) 2010. doi:10.1016/S0140-6736(10)61350-5. PMID 21067804. Randomized-trial meta-analysis supports statin/LDL lowering preventing occlusive vascular events. Does not support dismissing therapy as merely dashboard management.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England journal of medicine 2023. doi:10.1056/NEJMoa2307563. PMID 37952131. SELECT randomized trial supports cardiovascular event reduction in the studied overweight/obese population with existing cardiovascular disease; not direct evidence of mitochondrial repair or NAION mediation.
Luna-Marco C, de Marañon AM, Hermo-Argibay A, et al. Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes. Redox biology 2023. doi:10.1016/j.redox.2023.102849. PMID 37591012. A nonrandomized human study found improved leukocyte mitochondrial respiration and redox measures with GLP-1 RA treatment. Not proof of complete vascular/optic-nerve repair, but inconsistent with a blanket no-mitochondrial-benefit claim.
Grauslund J, Taha AA, Molander LD, et al. Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes. International journal of retina and vitreous 2024. doi:10.1186/s40942-024-00620-x. PMID 39696569. Danish T2D observational cohort supports an association of semaglutide with increased NAION risk; cannot identify the proposed causal mechanism, interaction with statins or high-risk subgroup bundle.
Simonsen E, Lund LC, Ernst MT, et al. Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study. Diabetes, obesity & metabolism 2025. doi:10.1111/dom.16316. PMID 40098249. Danish-Norwegian observational study supports low absolute excess NAION incidence and elevated relative risk in T2D; not an estimate for every indication/population and not proof of statin interaction.
Liu B, Zhu L, Zhong J, et al. The Association Between Phosphodiesterase Type 5 Inhibitor Use and Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis. Sexual medicine 2018. doi:10.1016/j.esxm.2018.03.001. PMID 29884471. Observational meta-analysis found no statistically significant overall association, with signals in some drug subgroups; uncertainty and confounding remain. Supports cautious association language, not a proven anatomy-dependent causal risk.

See the notice at the top of this page. Working hypothesis, not medical advice.